Salivary gland derived peptides as a new class of anti-inflammatory agents: review of preclinical pharmacology of C-terminal peptides of SMR1 protein

详细信息    查看全文

• 作者：Ronald D Mathison (1)
  Joseph S Davison (1)
  A Dean Befus (2)
  Daniel A Gingerich (3)
  
• 刊名：Journal of Inflammation
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：7
• 期：1
• 全文大小：1987KB
• 参考文献：1. Pedersen AM, Bardow A, Jensen SB, Nauntofte B: Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. / Oral Dis 2002, 8: 117-29. CrossRef
  2. Tenovuo J: Antimicrobial agents in saliva - protection for the whole body. / Journal of Dental Research 2002, 81: 807-09. CrossRef
  3. Barka T: Biologically active polypeptides in submandibular glands. / J Histochem Cytochem 1980, 28: 836-59.
  4. Rougeot C, Messaoudi M, Hermitte V, Rigault AG, Blisnick T, Dugave C, Desor D, Rougeon F: Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity. / Proc Natl Acad Sci USA 2003, 100: 8549-554. CrossRef
  5. Isenman L, Liebow C, Rothman S: The endocrine secretion of mammalian digestive enzymes by exocrine glands. / Am J Physiol 1999, 276: E223-32.
  6. Kongshavn PA, Lapp WS: Immunosuppressive effect of male mouse submandibular gland extracts on plaque-forming cells in mice: abolition by orchiectomy. / Immunology 1972, 22: 227-30.
  7. Kemp A, Mellow L, Sabbadini E: Suppression and enhancement of in vitro lymphocyte reactivity by factors in rat submandibular gland extracts. / Immunology 1985, 56: 261-67.
  8. Amico-Roxas M, Caruso A, Leone MG, Scifo R, Vanella A, Scapagnini U: Nerve growth factor inhibits some acute experimental inflammations. / Arch Int Pharmacodyn Ther 1989, 299: 269-85.
  9. Mathison R, Davison JS, Befus AD: Neuroendocrine regulation of inflammation and tissue repair by submandibular gland factors. / Immunol Today 1994, 15: 527-32. CrossRef
  10. Felten DL, Felten SY, Bellinger DL, Carlson SL, Ackerman KD, Madden KS, Olschowki JA, Livnat S: Noradrenergic sympathetic neural interactions with the immune system: structure and function. / Immunol Rev 1987, 100: 225-60. CrossRef
  11. Nance DM, Hopkins DA, Bieger D: Re-investigation of the innervation of the thymus gland in mice and rats. / Brain Behav Immun 1987, 1: 134-47. CrossRef
  12. Madden KS, Felten SY, Felten DL, Sundaresan PR, Livnat S: Sympathetic neural modulation of the immune system. I. Depression of T cell immunity in vivo and vitro following chemical sympathectomy. / Brain Behav Immun 1989, 3: 72-9. CrossRef
  13. Alito AE, Romeo HE, Baler R, Chuluyan HE, Braun M, Cardinali DP: Autonomic nervous system regulation of murine immune responses as assessed by local surgical sympathetic and parasympathetic denervation. / Acta Physiol Pharmacol Latinoam 1987, 37: 305-19.
  14. Ramaswamy K, Mathison R, Carter L, Kirk D, Green F, Davison JS, Befus D: Marked antiinflammatory effects of decentralization of the superior cervical ganglia. / J Exp Med 1990, 172: 1819-830. CrossRef
  15. Mathison R, Hogan A, Helmer D, Bauce L, Woolner J, Davison JS, Schultz G, Befus D: Role for the submandibular gland in modulating pulmonary inflammation following induction of systemic anaphylaxis. / Brain Behav Immun 1992, 6: 117-29. CrossRef
  16. Mathison R, Befus D, Davison JS: Removal of the submandibular glands increases the acute hypotensive response to endotoxin. / Circ Shock 1993, 39: 52-8.
  17. Mathison RD, Befus AD, Davison JS: A novel submandibular gland peptide protects against endotoxic and anaphylactic shock. / Am J Physiol 1997, 273: R1017-023.
  18. Rosinski-Chupin I, Tronik D, Rougeon F: High level of accumulation of a mRNA coding for a precursor-like protein in the submaxillary gland of male rats. / Proc Natl Acad Sci USA 1988, 85: 8553-557. CrossRef
  19. Morris KE, St Laurent CD, Hoeve RS, Forsythe P, Suresh MR, Mathison RD, Befus AD: Autonomic nervous system regulates secretion of anti-inflammatory prohormone SMR1 from rat salivary glands. / Am J Physiol Cell Physiol 2009, 296: C514-24. CrossRef
  20. Mathison R, Tan D, Oliver M, Befus D, Scott B, Davison JS: Submandibular gland peptide-T (SGP-T) inhibits intestinal anaphylaxis. / Dig Dis Sci 1997, 42: 2378-383. CrossRef
  21. Mathison RD, Malkinson T, Cooper KE, Davison JS: Submandibular glands: novel structures participating in thermoregulatory responses. / Can J Physiol Pharmacol 1997, 75: 407-13. CrossRef
  22. Nkemdirim M, Kubera M, Mathison R: Modulation of neutrophil activity by submandibular gland peptide-T (SGP-T). / Pol J Pharmacol 1998, 50: 417-24.
  23. Mathison RD, Sank C, Davison JS: Inhibition of leukocyte rolling by submandibular gland peptide-T (SGP-T). / Proc West Pharmacol Soc 1999, 42: 39-0.
  24. Morris K, Kuo B, Wilkinson MD, Davison JS, Befus AD, Mathison RD: Vcsa1 gene peptides for the treatment of inflammatory and allergic reactions. / Recent Pat Inflamm Allergy Drug Discov 2007, 1: 124-32. CrossRef
  25. Rosinski-Chupin I, Kuramoto T, Courty Y, Rougeon F, Serikawa T: Assignment of the rat variable coding sequence (VCS) gene family to chromosome 14. / Mamm Genome 1995, 6: 153-54. CrossRef
  26. Rosinski-Chupin I, Rougeon F: The gene encoding SMR1, a precursor-like polypeptide of the male rat submaxillary gland, has the same organization as the preprothyrotropin-releasing hormone gene. / DNA Cell Biol 1990, 9: 553-59. CrossRef
  27. Rougeot C, Rosinski-Chupin I, Rougeon F: Novel genes and hormones in salivary glands: From the gene for the submandibular rat1 protein (SMR1) precursor to receptor sites for SMR1 mature peptides. / Biomedical Reviews 1998, 9: 17-2.
  28. Dickinson DP, Thiesse M: cDNA cloning of an abundant human lacrimal gland mRNA encoding a novel tear protein. / Curr Eye Res 1996, 15: 377-86. CrossRef
  29. Isemura S: Nucleotide sequence of gene PBII encoding salivary proline-rich protein P-B. / J Biochem (Tokyo) 2000, 127: 393-98.
  30. Isemura S, Saitoh E: Nucleotide sequence of gene PBI encoding a protein homologous to salivary proline-rich protein P-B. / J Biochem (Tokyo) 1997, 121: 1025-030.
  31. Wisner A, Dufour E, Messaoudi M, Nejdi A, Marcel A, Ungeheuer MN, Rougeot C: Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. / Proc Natl Acad Sci USA 2006, 103: 17979-7984. CrossRef
  32. Davies KP, Tar M, Rougeot C, Melman A: Sialorphin (the mature peptide product of Vcsa1) relaxes corporal smooth muscle tissue and increases erectile function in the ageing rat. / BJU Int 2007, 99: 431-35. CrossRef
  33. Messaoudi M, Desor D, Nejdi A, Rougeot C: The endogenous androgen-regulated sialorphin modulates male rat sexual behavior. / Horm Behav 2004, 46: 684-91. CrossRef
  34. Tong Y, Tar M, Davelman F, Christ G, Melman A, Davies KP: Variable coding sequence protein A1 as a marker for erectile dysfunction. / BJU Int 2006, 98: 396-01. CrossRef
  35. Davies KP: The role of opiorphins (endogenous neutral endopeptidase inhibitors) in urogenital smooth muscle biology. / J Sex Med 2009, 6 (Suppl 3) : 286-91. CrossRef
  36. Rosinski-Chupin I, Huaulme JF, Rougeot C, Rougeon F: The transcriptional response to androgens of the rat VCSA1 gene is amplified by both binary and graded mechanisms. / Endocrinology 2001, 142: 4550-559. CrossRef
  37. Tong Y, Tar M, Melman A, Davies K: The opiorphin gene (ProL1) and its homologues function in erectile physiology. / BJU Int 2008, 102: 736-40. CrossRef
  38. Mathison R, Lo P, Moore G, Scott B, Davison JS: Attenuation of intestinal and cardiovascular anaphylaxis by the salivary gland tripeptide FEG and its D-isomeric analog feG. / Peptides 1998, 19: 1037-042. CrossRef
  39. Mathison RD, Befus AD, Davison JS, Woodman RC: Modulation of neutrophil function by the tripeptide feG. / BMC Immunol 2003, 4: 3. CrossRef
  40. Rifai Y, Elder AS, Carati CJ, Hussey DJ, Li X, Woods CM, Schloithe AC, Thomas AC, Mathison RD, Davison JS, Toouli J, Saccone GT: The tripeptide analog feG ameliorates severity of acute pancreatitis in a caerulein mouse model. / Am J Physiol Gastrointest Liver Physiol 2008, 294: G1094-099. CrossRef
  41. Bao F, John SM, Chen Y, Mathison RD, Weaver LC: The tripeptide phenylalanine-(d) glutamate-(d) glycine modulates leukocyte infiltration and oxidative damage in rat injured spinal cord. / Neuroscience 2006, 140: 1011-022. CrossRef
  42. Turesin F, Sadr A, Davison JS, Mathison R: The tripeptide FEG ameliorates systemic inflammatory responses to rat intestinal anaphylaxis. / BMC Physiol 2002, 2: 13. CrossRef
  43. Mathison RD, Christie E, Davison JS: The tripeptide feG inhibits leukocyte adhesion. / J Inflamm (Lond) 2008, 5: 6. CrossRef
  44. Dery RE, Mathison R, Davison J, Befus AD: Inhibition of allergic inflammation by C-terminal peptides of the prohormone submandibular rat 1 (SMR-1). / Int Arch Allergy Immunol 2001, 124: 201-04. CrossRef
  45. Dery RE, Ulanova M, Puttagunta L, Stenton GR, James D, Merani S, Mathison R, Davison J, Befus AD: Frontline: Inhibition of allergen-induced pulmonary inflammation by the tripeptide feG: a mimetic of a neuro-endocrine pathway. / Eur J Immunol 2004, 34: 3315-325. CrossRef
  46. Mathison R, Woodman R, Davison JS: Regulation of leukocyte adhesion to heart by the tripeptides feG and feG(NH2). / Can J Physiol Pharmacol 2001, 79: 785-92. CrossRef
  47. Mathison R, Lo P, Tan D, Scott B, Davison JS: The tripeptide feG reduces endotoxin-provoked perturbation of intestinal motility and inflammation. / Neurogastroenterol Motil 2001, 13: 599-03. CrossRef
  48. Mathison R: Submandibular gland peptides and the modulation of anaphylactic and endotoxic reactions. / Biomedical Reviews 1998, 9: 101-06.
  49. Mathison RD, Davison JS, Befus AD: The tripeptide feG reduces perturbation of intestinal motility provoked by anaphylaxis. / Proc West Pharmacol Soc 2001, 44: 157-58.
  50. Tan D, Rougeot C, Davison JS, Mathison R: The carboxamide feG(NH2) inhibits endotoxin perturbation of intestinal motility. / Eur J Pharmacol 2000, 409: 203-05. CrossRef
  51. Mathison R, Davison JS, Befus AD, Abraham WM: The tripeptide feG inhibits asthmatic reactions in sheep. In / Immunology 2004. Edited by: Monduzzi E. Montreal Medimond International Proceedings; 2004:515-19.
  52. DeClue AE, Schooley E, Nafe LA, Reinero CR: feG-COOH blunts eosinophilic airway inflammation in a feline model of allergic asthma. / Inflamm Res 2009, 58: 457-62. CrossRef
  53. Eberhardt JM, AE D, CR R: Chronic use of the immunomodulating tripeptide feG-COOH in experimental feline asthma. / Vet Immunol Immunopathol 2009, 132: 175-80. CrossRef
  54. John SM, Bao F, Chen Y, Mathison RD, Weaver LC: Effects of a novel tripeptide on neurological outcomes after spinal cord injury. / Neuroreport 2006, 17: 1793-796. CrossRef
  55. Mathison RD, Befus AD, Davison JS: Reduction in cardiovascular anaphylaxis by submandibular gland peptide-T. / Proc West Pharmacol Soc 1997, 40: 73-4.
  56. Fujishima S, Aikawa N: Neutrophil-mediated tissue injury and its modulation. / Intensive Care Med 1995, 21: 277-85. CrossRef
  57. Mathison RD, Davison JS: The tripeptide feG regulates the production of intracellular reactive oxygen species by neutrophils. / J Inflamm (Lond) 2006, 3: 9. CrossRef
  58. von Bültzingsl?wen I, Sollecito TP, Fox PC, Daniels T, Jonsson R, Lockhart PB, Wray D, Brennan MT, Carrozzo M, Gandera B, Fujibayashi T, Navazesh M, Rhodus NL, Schi?dt M: Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations. / Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007, 103: e1-5.
  59. Williams RC, Barnett AH, Claffey N, Davis M, Gadsby R, Kellett M, Lip GY, Thackray S: The potential impact of periodontal disease on general health: a consensus view. / Curr Med Res Opin 2008, 24: 1635-643. CrossRef
  60. Cullinan MP, Ford PJ, Seymour GJ: Periodontal disease and systemic health: current status. / Aust Dent J 2009, 54 (Suppl 1) : S62-9. CrossRef
  61. Lund EM, Armstrong PJ, Kirk CA, Kolar LM, Klausner JS: Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. / J Am Vet Med Assoc 1999, 214: 1336-341.
  62. Niemiec BA: Periodontal disease. / Top Companion Anim Med 2008, 23: 72-0. CrossRef
  63. Reiter AM, Brady CA, Harvey CE: Local and systemic complications in a cat after poorly performed dental extractions. / J Vet Dent 2004, 21: 215-21.
  64. DeBowes LJ, Mosier D, Logan E, Harvey CE, Lowry S, Richardson DC: Association of periodontal disease and histologic lesions in multiple organs from 45 dogs. / J Vet Dent 1996, 13: 57-0.
  65. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. / Nat New Biol 1971, 231: 232-35.
  66. Zarbock A, Ley K: Mechanisms and consequences of neutrophil interaction with the endothelium. / Am J Pathol 2008, 172: 1-. CrossRef
  67. Brady CA, Otto CM: Systemic inflammatory response syndrome, sepsis, and multiple organ dysfunction. / Vet Clin North Am Small Anim Pract 2001, 31: 1147-162. v-vi
  68. Belknap JK: The pharmacologic basis for the treatment of developmental and acute laminitis. / Vet Clin North Am Equine Pract 2010, 26: 115-24. CrossRef
  69. FIM Rationale and Proposed Guidelines for the Nutraceutical Research & Education Act - NREA [http://www.fimdefelice.org/archives/arc.researchact.html]
  
• 作者单位：Ronald D Mathison (1)
  Joseph S Davison (1)
  A Dean Befus (2)
  Daniel A Gingerich (3)
  
  1. Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, T2N 4N1, Calgary, Alberta, Canada
  2. 550A Heritage Medical Research Centre, Faculty of Medicine and Dentistry, University of Alberta, T6G 2S2, Edmonton, Alberta, Canada
  3. Turtle Creek Biostatistical Consulting, 2219 Wilmington Road, 45036, Lebanon, OH, USA
  
• ISSN：1476-9255

文摘

The limitations of steroidal and non steroidal anti-inflammatory drugs have prompted investigation into other biologically based therapeutics, and identification of immune selective anti-inflammatory agents of salivary origin. The traditional view of salivary glands as accessory digestive structures is changing as their importance as sources of systemically active immunoregulatory and anti-inflammatory factors is recognized. Salivary gland involvement in maintenance of whole body homeostasis is regulated by the nervous system and thus constitutes a "neuroendocrine axis". The potent anti-inflammatory activities, both in vivo and in vitro, of the tripeptide Phe-Glu-Gly (FEG) are reviewed. FEG is a carboxyl terminal peptide of the prohormone SMR1 identified in the rat submandibular salivary gland, The D-isomeric form (feG) mimics the activity of its L-isomer FEG. Macropharmacologically, feG attenuates the cardiovascular and inflammatory effects of endotoxemia and anaphylaxis, by inhibition of hypotension, leukocyte migration, vascular leak, and disruption of pulmonary function and intestinal motility. Mechanistically, feG affects activated inflammatory cells, especially neutrophils, by regulating integrins and inhibiting intracellular production of reactive oxygen species. Pharmacodynamically, feG is active at low doses (100 μg/kg) and has a long (9-12 hour) biological half life. As a therapeutic agent, feG shows promise in diseases characterized by over exuberant inflammatory responses such as systemic inflammatory response syndrome and other acute inflammatory diseases. Arthritis, sepsis, acute pancreatitis, asthma, acute respiratory inflammation, inflammatory bowel disease, and equine laminitis are potential targets for this promising therapeutic peptide. The term "Immune Selective Anti-Inflammatory Derivatives" (ImSAIDs) is proposed for salivary-derived peptides to distinguish this class of agents from corticosteroids and nonsteroidal anti-inflammatory drugs.